Because individual studies evaluating the role of quinidine in the maintenance of sinus rhythm after cardioversion from chronic atrial fibrillation have involved relatively few patients, a meta-analysis of randomized control trials was performed. Six trials published between 1970 and 1984 were selected by two blinded reviewers based on study design and statistical analysis. Data from these six trials involving 808 patients were pooled after testing for homogeneity of treatment effects across trials. Life table estimates of the percent of patients still in sinus rhythm at 3, 6, and 12 months after cardioversion were constructed for quinidine and control groups. The proportion of patients remaining in sinus rhythm in the quinidine group was 69O, 58%, and 50% at 3, 6, and 12 months postcardioversion respectively. The proportion of patients remaining in sinus rhythm in the control group was 45%, 33%, and 25% at the same time intervals. The pooled rate difference, or difference in proportion of patients in sinus rhythm between quinidine and control groups, was 24%, 23%, and 24% at 3, 6, and 12 months of follow-up (p<0.001 at all time intervals). The unadjusted total mortality rate in the quinidinetreated patients was 2.9%o and in the control group was 0.8%. The odds of dying in the quinidine-treated group were approximately three times that of the control group ("typical" odds ratio= 2.98, p<0.05). Thus, quinidine treatment is more effective than no antiarrhythmic therapy in suppressing recurrences of atrial fibrillation but appears to be associated with increased total mortality.
Several randomized trials have been published assessing the efficacy of quinidine in maintaining sinus rhythm after cardioversion. Because these randomized trials individually enrolled small numbers of patients, the present meta-analysis was undertaken to pool the results from several trials using contemporary biostatistical methods to obtain a more precise estimate of quinidine's effectiveness. In addition, this meta-analysis was performed to provide a more accurate estimate of quinidine-related mortality when the drug is used for the treatment of AF.
Methods

Acquisition of Data
To identify all randomized control trials (RCTs) of quinidine in maintaining sinus rhythm after cardioversion, the English and non-English language literature was searched from 1966 to July 1989, using the MEDLINE data bases of the National Library of Medicine. The MEDLINE strategy used the terms "quinidine," the chemical registry number for quinidine, and then was intersected with the terms "atrial fibrillation" or "atrial flutter." The result then was intersected with a broad strategy for retrieval of clinical trials. Initial selection of studies was made by two investigators (T.C.C. and P.H.) from the MEDLINE record and the entire article before the studies were blinded. Additional sources included references from papers identified in the above searches.
As reported in previous meta-analyses, studies that were considered potentially acceptable had the sources and results sections masked so that the decision to include or reject the paper could be made in a blinded fashion.8,9 Two investigators (S.E.C. and E.M.A.) then independently evaluated the methods and results of all trials using a previously published standardized analysis form. 10 Specific features of RCTs screened included trial entry criteria, demographics, methods, statistical analysis, major end points of the trial, and handling of withdrawals and side effects. Trials were included in this meta-analysis if both investigators agreed that the RCT met the following inclusion criteria: 1) patients with chronic AF (dysrhythmia lasting longer than 72 hours) undergoing cardioversion were randomized to quinidine or control treatment groups; 2) the trial followed patients longitudinally to assess the efficacy of quinidine in maintaining sinus rhythm, and these data were available in a form that permitted calculation of the percentage of patients remaining in sinus rhythm at one or more predetermined times after cardioversion (3, 6 , or 12 months); 3) the minimum follow-up time was 3 months postcardioversion; and 4) digoxin was the only other antiarrhythmic agent administered simultaneously. Exclusion criteria included absence of randomization and unclear descriptions of the treatment regimens for the quinidine and control groups. Studies evaluating the effect of quinidine in reject log was maintained of studies that did not meet the above criteria.
Statistics
Kaplan-Meier life-table techniques were used to estimate the probability of maintaining sinus rhythm for the quinidine and control group at 3, 6, or 12 months postcardioversion.1" Patients followed longitudinally in each study are referred to herein as the long-term treatment group, and the data were analyzed by the intention-to-treat method. Patients who withdrew from the study or died were treated as recurrences of AF unless their rhythm was known to be sinus rhythm at the time of their death, in which case their data were treated as censored events in the Kaplan-Meier analysis.
Pooled estimates of the percentage of patients remaining in sinus rhythm across trials at 3, 6, and 12 months postcardioversion were calculated in the following manner, which provided a correction factor for interstudy variability: X (St. WO) Pt= Mortality data were collected on patients who were randomized and received study medication even if the patient did not achieve sinus rhythm after cardioversion or had no long-term follow-up. This group will be called the full-exposure group; analysis of mortality data in this group includes the number of patients who were randomized to and received quinidine in the precardioversion period and therefore were at risk for mortality during this interval. Mortality data in the long-term treatment group also were tabulated in this meta-analysis and similar calculations performed. The long-term treatment group is smaller than the full-exposure group, because it excludes patients who failed to achieve sinus rhythm after cardioversion and patients who experienced adverse effects shortly after starting quinidine.
For each of the various cardiac diagnoses noted in the trials, we tested whether the proportion of patients in the quinidine group with a given diagnosis was equal to 0.5 using a normal approximation to the binomial distribution.
Results
Characteristics of Trials Analyzed
The literature search and review of references identified 52 papers addressing quinidine's effectiveness in maintaining sinus rhythm after cardioversion. Six of these studies met criteria for inclusion in the meta-analysis.17-22 The remaining 46 reports were not included in this meta-analysis for the following reasons: the study did not allocate patients randomly to treatment versus control groups (n = 24); the study did not include a concurrent control group, or the study design compared quinidine versus another antiarrhythmic agent rather than control therapy (n=12); the study group consisted of patients with acute AF rather than chronic AF (n=2); or results were presented in anecdotal or case report format (n=8). The six selected trials were published between 1970 and 1984 and involved 808 randomized patients. Characteristics of the six RCTs are shown in Table 1 . Patient ages were reported in four studies and ranged from 15 to 79 years (mean, 53). The duration of AF in patients enrolled in the six RCTs ranged from less than 1 month to up to 10 years; few patients had been in AF for longer than 3 years before cardioversion. In three papers, details of the duration of AF in the two treatment groups were provided, and there were no significant differences in the duration of AF between the quinidine and control groups in any of those trials. 19, 20, 22 The various cardiac diagnoses and possible etiologies of AF in each studiy are shown in Table 2 .
Valvular heart disease, primarily rheumatic, existed in 52% of the randomized population, with individual studies having from 31% to 69% of patients with this underlying process. Ischemia and "lone" AF were representative cardiac diagnoses of 16% and 12% of dosages.18-20,22 Desired quinidine levels varied from patients, respectively. Slightly more patients with 1-3 mg/l in the paper by Hartel et al19 to 4-6 mg/I in ischemic heart disease or thyroid dysfunction were the paper by Hillestad et al. 20 Only the paper by randomized to quinidine as opposed to control, but Byrne-Quinn and Wing18 reported the actual quinithese differences were not statistically significant. dine levels measured (mean of 2.2 mg/l, which was in This suggests that randomization was successful in the middle of the therapeutic range for the assay distributing patients with various underlying diagused) and did not find a statistically significant difnoses approximately equally to quinidine and control ference in quinidine levels in those patients relapsing groups. Only limited data on the relative degree of to AF and those patients remaining in sinus rhythm.
illness in the two treatment groups was provided in Concurrent digoxin therapy was optional in all the six RCTs. Two papers estimated heart volume trials and generally was withheld for at least 2 days from the chest radiograph and found similar values before cardioversion. None of the trials reported for the quinidine and control groups.20 ' reasons, and these remaining 727 patients (90% of the original group) comprise the long-term treatment group. Reasons for exclusion included failure to achieve sinus rhythm (58 patients), intractable side effects (six patients), death after randomization and no longitudinal data available (three patients), and improper randomization (one patient). In addition, the trial of Byrne-Quinn and Wing18 excluded five patients who achieved pharmacological conversion on quinidine.
The main measure of efficacy of quinidine therapy was objective determination of rhythm status at preset follow-up times. Although some studies had many time points for follow-up, only the data at 3, 6, and 12 months were used for the calculations. Kaplan-Meier estimates of the proportion of patients in sinus rhythm are shown in Table 3 for each trial along with the RD for individual trials at each interval (a measure of treatment effect). Although all six trials had 3-month follow-up data, only four had 6-month data, and three followed patients for 1 year. Three months postcardioversion, 69.4% of quinidinetreated patients and 45.1% of control patients remained in sinus rhythm. The calculated pooled RD (after correcting for individual study variances) was 23.6%, indicating treatment benefit in favor of the quinidine-treated group. At 6 months postcardioversion, 57.7% and 33.3% of patients were in sinus rhythm in the quinidine and control groups, respectively. The pooled RD of 23.4% was virtually the same as at the 3-month time interval. Data at 12 months revealed 50.2% of quinidine-treated patients and 24.7% of control patients in sinus rhythm. The 1-year pooled RD was 24.4% in favor of quinidine. Figure 1 displays the pooled estimates of the proportion of patients in sinus rhythm and 95% confidence interval for quinidine and control groups at 3, 6, and 12 months. Despite a continual decrease in the percentage of patients remaining free of AF, quinidine maintained a significant treatment advantage over control (p<0.001 at all time intervals).
As noted in "Methods," patients who withdrew from the trial or died were treated as recurrences of AF unless their rhythm was known to be sinus at or near the time of withdrawal or death, so the RDs noted above represent the minimal treatment benefit of quinidine in maintaining sinus rhythm. Seventeen patients (2.3% of total study group) were potentially misclassified by this algorithm, because no information was available about their cardiac rhythm at the time of withdrawal or death. Reclassifying these 17 patients (14 quinidine and three control) as remaining in sinus rhythm (censored in Kaplan-Meier analysis) yields the maximum potential treatment benefit of quinidine with RDs of 26.4% at 3 months, 28.3% at 6 months, and 29.0% at 12 months.
In pooling the RD results from the six trials, r, a factor adjusting for study heterogeneity, was calcu- lated. At 3, 6, and 12 months after cardioversion, the calculation of X indicated that no adjustment to the pooled RD was required because of relative study homogeneity.
Adverse Reactions to Treatment
Side effects related to quinidine were common and included diarrhea, syncope, and pyrexia. Sixty-six of the 373 (18%) patients receiving quinidine in the long-term treatment group reported adverse reactions, and 32 (9%) discontinued use of the medication.
Deaths were observed in both treatment and control groups. In the full-exposure group, 12 patients randomized to the quinidine group and three patients randomized to the control group died, yielding an unadjusted mortality rate of 2.9% for the quinidine group and 0.8% for the control group. Mortality data and calculations are shown in Table 4 . The precise cause of death in the quinidine-treated patients was known in seven of 12 cases and included sudden cardiac death (n=3), myocardial infarction (n = 1), cerebrovascular accident (n =2), and suicide (n = 1). In FIGURE 2 . Odds ratios (Quinidine:Control) for total mortality in full-exposure groups ofsix randomized control trials (RCT) (see are depicted (small squares) along with pooled ("typical" odds ratio) result from all trials (large square). Horizontal lines depict 95% confidence interval. Pooled odds ratio and its 95% confidence interval fall to the right of the vertical line, indicating a significant increase in total mortality in quinidinetreated group as compared with control group three times greater than on no antiarrhythmic therapy and that a relatively homogeneous observation was made among the six trials (Figure 2 ). If only mortality from the long-term treatment group were analyzed, the unadjusted mortality rate was 2.4% for the quinidine group and 0.6% for the control group. The typical OR was 3.1 (95% confidence interval, 0.9-10.4; p=0.07). Although this value did not reach conventional statistical significance, it too indicates a strong trend toward increased mortality in the group assigned to quinidine. This meta-analysis of RCTs reveals a statistically significant treatment benefit of quinidine in preventing recurrences of AF. The treatment effect is apparent 3 months after restoration of sinus rhythm and persists throughout the 1-year follow-up period. The risk of recurrence of AF is greatest during the first 3 months after cardioversion, and quinidine appears to diminish that risk. For these six studies, approximately 69%, 58%, and 50% of quinidine-treated patients remained in sinus rhythm 3, 6, and 12 months postcardioversion. The proportion of control patients remaining in sinus rhythm at these same intervals was 45%, 33%, and 25%, representing an absolute reduction of approximately 24% compared with the quinidine-treated group at each interval. The play of chance is an unlikely explanation for the results observed in this study. Although the total number of patients analyzed is small compared with other meta-analyses, such as those studying the use of beta-blockers after myocardial infarction, the treatment benefit observed is large and relatively consistent from study to study.14 Unfortunately, not enough data were available to analyze the maintenance of sinus rhythm in subsets of patients with various underlying cardiac diagnoses. This study also does not allow for comparison of short-and longacting quinidine preparations. Another limitation of this meta-analysis is the relatively short follow-up period. Few data concerning maintenance of sinus rhythm are available from nonrandomized trials beyond 2-3 years after cardioversion, but available data suggest dismal results.24 Because patients are at risk for emboli and development of symptoms anytime AF recurs, long-term data may be useful to collect in the future.
Discussion
As noted by Yusuf et al,14 a meta-analysis of clinical trials is most representative of the true treatment effect both qualitatively and quantitatively when nearly all randomized patients are available for analysis. Potential sources of incomplete data collection include: 1) failure to identify one or more randomized clinical trials (published or unpublished because of negative results), 2) inappropriate withdrawal of some randomized patients from the final report, and 3) failure to report important clinical events such as mortality or clinical status when patients are withdrawn from the trial. Regarding the first point, our method of collection of trials probably identified all published reports but would have overlooked unpublished reports from sources such as pharmaceutical firms and scientific symposia. However, if there were a publication bias, we would have expected trials with a larger sample size to show systematically a smaller RD,23 and this was not observed in our analysis. In response to the second point, 22 randomized patients in this meta-analysis were withdrawn (13 quinidine, nine control) from the long-term treatment group because of a combination of quinidine intolerance, death after randomization and treatment, pharmacological conversion to sinus rhythm, and loss to follow-up. Even if all 22 patients were considered to have sustained recurrences of AF and the pooled RD were recalculated, a slightly reduced but still significant treatment benefit in favor of quinidine would be present at all time intervals analyzed (22.3% at 3 months, 20.8% at 6 months, and 22.0% at 12 months). Lastly, in response to the third point, our assumption of recurrent AF on withdrawal from the trial unless otherwise specified by the authors might have contributed to a systematic underestimation of the true treatment benefit of quinidine, but the qualitative results would be unchanged.
The total mortality rate of the full-exposure group was 2.9% in quinidine-treated patients and 0.8% in control patients, yielding a pooled OR of 2.98. Ideally, the above mortality data would have been analyzed by a comparison of survival curves using the log-rank test. Because the primary data were not by guest on April 15, 2017 http://circ.ahajournals.org/ Downloaded from presented in a time-to-failure format, the OR method was used. The tendency toward increased mortality in the quinidine-treated group was noted in each individual study but was a more powerful observation when the data were pooled. Although it is theoretically possible that the mortality difference could have arisen as a result of bias in the treatment groups, this seems unlikely for the following reasons: 1) The trials were all randomized, 2) the total sample size was approximately 800 patients, 3) there was no significant difference in the distribution of cardiac diagnoses and simple measures of degree of illness (in those RCTs in which such information was available), and 4) the trend toward increased mortality in the quinidine group was a consistent finding among all six RCTs (x, for heterogeneity= 1.6, df=5, p=0.9). The mechanism of increased mortality was known to be sudden cardiac death in three of seven quinidine-treated patients in which the cause of death was specified by the authors. A lethal ventricular arrhythmia may have been the cause of death in some or all of the five other quinidine-treated patients in which the mode of death was unclear. The two other cardiac arrests occurring in patients receiving quinidine (but not included in the analysis as noted above) highlight the The mortality rates in the control groups in the 10 postinfarction RCTs analyzed by Hine et al8 ranged from 2% to 22% and are higher than the mortality rates in the control groups of the six RCTs in AF patients reported herein (range, 0-2.6%). Nevertheless, an apparent adverse effect on mortality was observed in the quinidine-treated patients in this meta-analysis. This disturbing observation is of borderline statistical significance in part because of the low event rate in the AF patients, as would be expected in comparison with postinfarction patients. To confirm this observation, a randomized trial with a large sample size and long enough follow-up would need to be performed. Based on the rates in this meta-analysis, approximately 1,500 patients would need to be randomized to detect the difference between a 1% mortality in the control group and a 3% mortality in the quinidine group (a=0.05, power=90%). Because of the ethical concerns raised by this meta-analysis, one would want to include a sequential stopping rule.
Although reports of death in patients on quinidine have been available for more than 15 years, many physicians may not be fully aware of the data and many do not inform their patients of the potential dangers of quinidine. At least part of the mortality in patients taking quinidine is related to sudden cardiac death. Prolongation of the QT interval has been observed in patients before sudden death, and patients receiving quinidine who develop hypokalemia may be particularly prone to serious ventricular rhythm disturbances.27,28 Although not specified by the authors, some of the mortality in the quinidinetreated patients may have resulted from hypokalemia from diuretic use29 or concurrent medical illnesses (e.g., pneumonia, carcinoma). In addition, because at least four of the trials were conducted before reports of a quinidine-digoxin pharmacokinetic interaction, some of the arrhythmia-related deaths may have been a result of digoxin toxicity.30 Furthermore 
Calculation of Odds Ratios14
In a trial of T patients, N1 were randomly assigned to quinidine treatment, and M1 died; the observed number of deaths, 0, is compared with the expected number, E, where E=(N1M1)/T. If quinidine treatment did not affect mortality, the quantity O-E would differ only randomly from zero with variance (V).
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If quinidine treatment truly were associated with an increased mortality, that tendency might be obscured or reversed by chance in an individual study. However, the overall trend should become more apparent when the sum of the individual O-E values is determined. This sum has variance equal to the sum of the individual study variances (SIV) and has an SD equal to the square root of the total variance. Formal statistical testing is performed by calculating z where Z individual 0-E values SD and comparing z to a table of normal distribution. The typical odds ratio (OR) of death among those patients assigned to quinidine treatment is calculated as follows: Iz OR=exp ( ) with approximate 95% confidence interval given by: /z 1.96 exp -_ Heterogeneity between treatment effects in different trials can be estimated by subtracting the x2 statistic for the overall result from the sum of x2 statistics for each separate trial result in a group of k trials with df=k-1. Such tests of heterogeneity are rather insensitive to real treatment differences and therefore are of limited value.
